

Att: Dr. Henning Gädeke, Chair of the EDCTP Association Board and the Global Health EDCTP3

c/o Dr. Michael Makanga, Executive Director of the Global Health EDCTP3 Joint Undertaking

Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

25 September 2025

Letter of endorsement for the proposal “TESA network: Capacity-building for strengthening Epidemic Preparedness for trials of excellence in Southern Africa”

Dear Sir/Madam,

On behalf of FUNDACAO MANHICA (CISM), PIC 954910390, established on RUA 12 BAIRRO CAMBEVE DISTRITO DA MANHICA, VILA DA MANHICA MAPUTO 1929, Mozambique, and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

CISM is a consolidated research center, specialising in transmissible diseases prevalent in Mozambique. It focuses particularly on the main causes of morbidity and mortality in the country, such as malaria, HIV/AIDS, tuberculosis and bacterial diseases.

CISM's activities focus on research, and it has the necessary support services (laboratory, information technology, data management and analysis) and research platforms (geographic and demographic surveillance, and morbidity surveillance) to facilitate this. Through these activities, CISM aims to promote and carry out biomedical research in priority health areas, safeguarding the health of vulnerable populations and contributing to the achievement of SDG 3 (Ensure healthy lives and promote well-being for all at all ages).

In the event of a pandemic outbreak, CISM will consolidate its research infrastructure and facilities, as well as making its team of experienced researchers available. Building on its experience of the COVID-19 outbreak and its role as Scientific Lead of Work Package 2, CISM will leverage information sharing through the network and make best practices available to its members. The TESA IV project will be implemented internally in collaboration with the National Institute of Health (INS) and the Ministry of Health, facilitating its impact on public health policy.

CISM will provide scientific leadership and support the expansion of TESA's work into epidemic preparedness and response. CISM will develop a regional, pandemic-ready network of clinical trial sites with surge capacity, enabling the rapid initiation of multicentre trials during outbreaks. This effort will begin with a thorough assessment of the preparedness and response activities of participating countries' researchers, universities, and NPHIs. An action plan will then be developed and implemented to address any identified weaknesses and needs. Communication channels will be explored and promoted between research institutes, MoHs, and NPHIs to enable emergency response and epidemic preparedness in the region. A roadmap will be established to formalise relationships between research institutions, MoHs, and NPHIs

within each country. Regional and international partnerships will be established to sustain knowledge exchange, innovation, continuous learning, and emergency response preparedness. Regional efforts will be aligned with global health security frameworks.


CISM will provide laboratory activities where the tests will be conducted, as well as **laboratory equipment and freezers and fridges** for archiving study specimens. Access will be provided to a Data Management Centre where participants' **data will be captured**, cleaned and analysed, and a vehicle will be provided for transporting study participants and specimens. The MoH will **provide free access to the primary healthcare clinic**, where study participants will be enrolled and monitored for four years, and to the laboratory, where some of the tests will be conducted.

We estimate the total value of the **in-kind contributions to be €500,000** over the five-year grant period. This contribution will be made through payment of salaries and benefits for some staff not paid by the project, as well as the use and maintenance of laboratory equipment and clinical facilities, and access to data sets, data analysis and management, and office space. The in-kind contribution will be made within the scope of Work Packages 2, 3, 4 and 5.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Dr. Francisco Saute

Director General